Updated on 13 January 2015
The product enjoys patent protection until 2031
Singapore: Australia-based Cellmid has received patent approval from IP Australia for method of treatment or prevention of hair loss. The treatment can also enhance hair growth.
This patent protects the use of midkine and the closely related protein pleiotrophin for use as hair loss and/or hair growth treatments. The granted claims cover topical formulations of all kinds, including shampoos, conditioners, creams and lotions with protection until 2031.
This patent family adds to the already considerable intellectual property assets of Cellmid's wholly owned anti-aging hair growth subsidiary, Advangen, which include patent protection and extensive know-how around its FGF5 inhibiting technologies, cell based assays, formulations and brands.